Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Advances in Therapy
Published in: Advances in Therapy 6/2020

Open Access 01-06-2020 | Ovarian Cancer | Review

Malignant Transformation and Associated Biomarkers of Ovarian Endometriosis: A Narrative Review

Authors: Liudmila M. Mikhaleva, Aleksandr I. Davydov, Olga I. Patsap, Elizaveta V. Mikhaylenko, Vladimir N. Nikolenko, Margarita E. Neganova, Sergey G. Klochkov, Siva G. Somasundaram, Cecil E. Kirkland, Gjumrakch Aliev

Published in: Advances in Therapy | Issue 6/2020

Login to get access

Abstract

This review focuses on pathogenesis of endometriosis, its possible biomarkers and role in endometriosis-associated ovarian cancer. We analyzed various databases to obtain new insights, theories, and biomarkers associated with endometriosis. There are several theories of endometriosis development and biomarker changes including atypical forms. A number of studies have attempted to establish specific, reliable biomarkers to help diagnose endometriosis and endometriosis-associated diseases on the basis of different pathogenetic pathways. Nevertheless, despite intensive research extending even to the molecular level, the origin, natural history, malignant transformation, and laboratory management of endometriosis and related diseases are not yet clearly defined. Therefore, early laboratory diagnoses of endometriosis, its atypical form, and endometriosis-associated ovarian tumors are important problems that require further study in the context of advanced therapeutic strategies to provide maximal health benefits to patients.
Literature
1.
Adamyan L, Andreeva E, Apolikhina I, et al. Endometrioz: diagnostika, lechenie i reabilitatsiya: federal’nye klinicheskie rekomendatsii po vedeniyu bol’nykh. Izd-vo Nauchnogo tsentra akusherstva, ginekologii i perinatologii im. V.I.Kulakova, Moscow 2013.
2.
Zaĭratiants OV, Adamian LV, Andreeva EN, et al. Molecular biological features of ectopic and eutopic endometrium in genital endometriosis. Arkh Patol. 2010;72:6–12.
3.
Gajbhiye R, Bendigeri T, Ghuge A, et al. Panel of autoimmune markers for noninvasive diagnosis of minimal-mild endometriosis. Reprod Sci. 2017;24:413–20.PubMedCrossRef
4.
Socolov R, Socolov D, Sindilar A, Pavaleanu I. An update on the biological markers of endometriosis. Minerva Ginecol. 2017;69:462–7.PubMed
5.
Pearce CL, Stram DO, Ness RB, et al. Population distribution of lifetime risk of ovarian cancer in the United States. Cancer Epidemiol Biomark Prev. 2015;24:671–6.CrossRef
6.
Ñiguez Sevilla I, Machado Linde F, Marín Sánchez MDP, et al. Prognostic importance of atypical endometriosis with architectural hyperplasia versus cytologic atypia in endometriosis-associated ovarian cancer. J Gynecol Oncol. 2019;30:e63.PubMedPubMedCentralCrossRef
7.
Munksgaard PS, Blaakaer J. The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. Gynecol Oncol. 2012;124:164–9.PubMedCrossRef
8.
Vinatier D, Cosson M, Dufour P. Is endometriosis an endometrial disease? Eur J Obstet Gynecol Reprod Biol. 2000;91:113–25.PubMedCrossRef
9.
Vinatier D, Dufour P, Leroy JL. The mechanisms of endometriosis. Rev Prat. 1999;49:254–7.PubMed
10.
Larosa M, Facchini F, Pozzoli G, Leone M, Grande M, Monica B. Endometriosis: aetiopathogenetic basis. Urologia. 2010;77(Suppl 17):1–11.PubMedCrossRef
11.
Drosdzol A, Skrzypulec V. Endometriosis in pediatric and adolescent gynecology. Ginekol Pol. 2008;79:133–6.PubMed
12.
13.
Aznaurova YB, Zhumataev MB, Roberts TK, Aliper AM, Zhavoronkov AA. Molecular aspects of development and regulation of endometriosis. Reprod Biol Endocrinol. 2014;12:50.PubMedPubMedCentralCrossRef
14.
Macer ML, Taylor HS. Endometriosis and infertility: a review of the pathogenesis and treatment of endometriosis-associated infertility. Obstet Gynecol Clin North Am. 2012;39:535–49.PubMedPubMedCentralCrossRef
15.
Adachi M, Nasu K, Tsuno A, Yuge A, Kawano Y, Narahara H. Attachment to extracellular matrices is enhanced in human endometriotic stromal cells: a possible mechanism underlying the pathogenesis of endometriosis. Eur J Obstet Gynecol Reprod Biol. 2011;155:85–8.PubMedCrossRef
16.
Laganà AS, Vitale SG, Salmeri FM, et al. Unus pro omnibus, omnes pro uno: a novel, evidence-based, unifying theory for the pathogenesis of endometriosis. Med Hypotheses. 2017;103:10–20.PubMedCrossRef
17.
Lin Q, Ding SJ, Zhu TH, Li TT, Huang XF, Zhang XM. Role and clinical significance of coagulation and inflammatory factors in moderate and severe ovarian endometriosis. Zhonghua Fu Chan Ke Za Zhi. 2018;53:167–71.PubMed
18.
Lushnikova A. Clinico-morphological analysis and immunohistochemical characteristics of inner end external genital endometriosis. Ph.D. dissertation, Institute of Regional Pathology and Pathomorphology 2012.
19.
Vitale SG, Capriglione S, Peterlunger I, et al. The role of oxidative stress and membrane transport systems during endometriosis: a fresh look at a busy corner. Oxid Med Cell Longev. 2018;2018:7924021.PubMedPubMedCentralCrossRef
20.
Jiang Q-Y, Wu R-J. Growth mechanisms of endometriotic cells in implanted places: a review. Gynecol Endocrinol. 2012;28:562–7.PubMedCrossRef
21.
Lin Y-J, Lai M-D, Lei H-Y, Wing L-YC. Neutrophils and macrophages promote angiogenesis in the early stage of endometriosis in a mouse model. Endocrinology. 2006;147:1278–86.PubMedCrossRef
22.
Bergqvist A, Bruse C, Carlberg M, Carlström K. Interleukin 1beta, interleukin-6, and tumor necrosis factor-alpha in endometriotic tissue and in endometrium. Fertil Steril. 2001;75:489–95.PubMedCrossRef
23.
Sacco K, Portelli M, Pollacco J, Schembri-Wismayer P, Calleja-Agius J. The role of prostaglandin E2 in endometriosis. Gynecol. 2012;28:134–8.
24.
Pedraza C, Geberhiwot T, Ingerpuu S, et al. Monocytic cells synthesize, adhere to, and migrate on laminin-8 (alpha 4 beta 1 gamma 1). J Immunol Baltim. 2000;165:5831–8.CrossRef
25.
Lessey BA, Castelbaum AJ, Sawin SW, et al. Aberrant integrin expression in the endometrium of women with endometriosis. J Clin Endocrinol Metab. 1994;79:643–9.PubMed
26.
Hinck L, Näthke IS, Papkoff J, Nelson WJ. Dynamics of cadherin/catenin complex formation: novel protein interactions and pathways of complex assembly. J Cell Biol. 1994;125:1327–40.PubMedCrossRef
27.
Shaco-Levy R, Sharabi S, Benharroch D, Piura B, Sion-Vardy N. Matrix metalloproteinases 2 and 9, E-cadherin, and beta-catenin expression in endometriosis, low-grade endometrial carcinoma and non-neoplastic eutopic endometrium. Eur J Obstet Gynecol Reprod Biol. 2008;139:226–32.PubMedCrossRef
28.
Ris HW. The integration of a comprehensive medical program in a juvenile correctional institution. J Am Med Womens Assoc (1972). 1975;30:367–78.
29.
Matsuzaki S, Darcha C. Involvement of the Wnt/β-catenin signaling pathway in the cellular and molecular mechanisms of fibrosis in endometriosis. PLoS One. 2013;8:e76808.PubMedPubMedCentralCrossRef
30.
Ueda M, Yamashita Y, Takehara M, et al. Gene expression of adhesion molecules and matrix metalloproteinases in endometriosis. Gynecol Endocrinol. 2002;16:391–402.PubMedCrossRef
31.
32.
Béliard A, Donnez J, Nisolle M, Foidart JM. Localization of laminin, fibronectin, E-cadherin, and integrins in endometrium and endometriosis. Fertil Steril. 1997;67:266–72.PubMedCrossRef
33.
Poncelet C, Leblanc M, Walker-Combrouze F, et al. Expression of cadherins and CD44 isoforms in human endometrium and peritoneal endometriosis. Acta Obstet Gynecol Scand. 2002;81:195–203.PubMedCrossRef
34.
Fujimoto J, Ichigo S, Hori M, Tamaya T. Alteration of E-cadherin, alpha- and beta-catenin mRNA expression in human uterine endometrium during the menstrual cycle. Gynecol Endocrinol. 1996;10:187–91.PubMedCrossRef
35.
36.
Teague EMCO, Print CG, Hull ML. The role of microRNAs in endometriosis and associated reproductive conditions. Hum Reprod Update. 2010;16:142–65.PubMedCrossRef
37.
38.
Nothnick WB, Swan K, Flyckt R, Falcone T, Graham A. Human endometriotic lesion expression of the miR-144-3p/miR-451a cluster, its correlation with markers of cell survival and origin of lesion content. Sci Rep. 2019;9:8823.PubMedPubMedCentralCrossRef
39.
40.
Hadfield RM, Mardon HJ, Barlow DH, Kennedy SH. Endometriosis in monozygotic twins. Fertil Steril. 1997;68:941–2.PubMedCrossRef
41.
Stefansson H, Geirsson RT, Steinthorsdottir V, et al. Genetic factors contribute to the risk of developing endometriosis. Hum Reprod. 2002;17:555–9.PubMedCrossRef
42.
43.
Chang CY-Y, Chen Y, Lai M-T, et al. BMPR1B up-regulation via a miRNA binding site variation defines endometriosis susceptibility and CA125 levels. PLoS One. 2013;8:e80630.PubMedPubMedCentralCrossRef
44.
Gupta D, Hull ML, Fraser I, et al. Endometrial biomarkers for the non-invasive diagnosis of endometriosis. Cochrane Database Syst Rev. 2016;4:CD012165.PubMed
45.
Nisenblat V, Prentice L, Bossuyt PMM, Farquhar C, Hull ML, Johnson N. Combination of the non-invasive tests for the diagnosis of endometriosis. Cochrane Database Syst Rev. 2016;7:CD012281.PubMed
46.
Fiala L, Bob P, Raboch J. Oncological markers CA-125, CA 19-9 and endometriosis. Medicine (Baltimore). 2018;97:e13759.CrossRef
47.
48.
Fassbender A, Vodolazkaia A, Saunders P, et al. Biomarkers of endometriosis. Fertil Steril. 2013;99:1135–45.PubMedCrossRef
49.
Fassbender A, Dorien O, De Moor B, et al. Biomarkers of endometriosis. In: Harada T, editor. Endometriosis: pathogenesis and treatment. Tokyo: Springer Japan; 2014. p. 321–339.
50.
D’Hooghe TM, Mihalyi AM, Simsa P, et al. Why we need a noninvasive diagnostic test for minimal to mild endometriosis with a high sensitivity. Gynecol Obstet Invest. 2006;62:136–8.PubMedCrossRef
51.
May KE, Conduit-Hulbert SA, Villar J, Kirtley S, Kennedy SH, Becker CM. Peripheral biomarkers of endometriosis: a systematic review. Hum Reprod Update. 2010;16:651–74.PubMedPubMedCentralCrossRef
52.
53.
Rogers PAW, D’Hooghe TM, Fazleabas A, et al. Defining future directions for endometriosis research: workshop report from the 2011 World Congress of Endometriosis in Montpellier, France. Reprod Sci. 2013;20:483–99.PubMedPubMedCentralCrossRef
54.
Rogers PAW, D’Hooghe TM, Fazleabas A, et al. Priorities for endometriosis research: recommendations from an international consensus workshop. Reprod Sci. 2009;16:335–46.PubMedCrossRef
55.
D’Hooghe T, Vodolazkaia A, Kyama C, Mwenda J, Simoens S. Health economics of endometriosis. In: Rombauts L, Tsaltas J, Maher P, Healy D, editors. Endometriosis. Malden: Blackwell; 2008. p. 1–16.
56.
Zetterberg H. Blood-based biomarkers for Alzheimer’s disease—an update. J Neurosci Methods. 2019;319:2–6.PubMedCrossRef
57.
Surinova S, Schiess R, Hüttenhain R, Cerciello F, Wollscheid B, Aebersold R. On the development of plasma protein biomarkers. J Proteome Res. 2011;10:5–16.PubMedCrossRef
58.
Othman EE-DR, Hornung D, Al-Hendy A. Biomarkers of endometriosis. Expert Opin Med Diagn. 2008;2:741–52.CrossRef
59.
60.
Hoskins W, Perez C, Young R, Barakat R, Markman M, Randall M, editors. Principles and practice of gynecologic oncology. 4th ed. Philadelphia: LWW; 2004.
61.
Ünsal M, Kimyon Comert G, Karalok A, et al. The preoperative serum CA125 can predict the lymph node metastasis in endometrioid-type endometrial cancer. Ginekol Pol. 2018;89:599–606.PubMedCrossRef
62.
Crosby DA, Glover LE, Martyn F, Wingfield M. CA125 measured during menstruation can be misleading. Ir Med J. 2018;111:738.PubMed
63.
Akinwunmi BO, Babic A, Vitonis AF, et al. Chronic medical conditions and CA125 levels among women without ovarian cancer. Cancer Epidemiol Biomark Prev. 2018;27:1483–90.CrossRef
64.
Hirsch M, Duffy J, Davis CJ, Nieves Plana M, Khan KS, International Collaboration to Harmonise Outcomes, and Measures for Endometriosis. Diagnostic accuracy of cancer antigen 125 for endometriosis: a systematic review and meta-analysis. BJOG. 2016;123:1761–8.PubMedCrossRef
65.
Hirsch M, Duffy JMN, Deguara CS, Davis CJ, Khan KS. Diagnostic accuracy of cancer antigen 125 (CA125) for endometriosis in symptomatic women: a multi-center study. Eur J Obstet Gynecol Reprod Biol. 2017;210:102–7.PubMedCrossRef
66.
Karimi-Zarchi M, Dehshiri-Zadeh N, Sekhavat L, Nosouhi F. Correlation of CA-125 serum level and clinico-pathological characteristic of patients with endometriosis. Int J Reprod Biomed. 2016;14:713–8.CrossRefPubMedPubMedCentral
67.
Tuten A, Kucur M, Imamoglu M, et al. Copeptin is associated with the severity of endometriosis. Arch Gynecol Obstet. 2014;290:75–82.PubMedCrossRef
68.
Hsu CC, Yang BC, Wu MH, Huang KE. Enhanced interleukin-4 expression in patients with endometriosis. Fertil Steril. 1997;67:1059–64.PubMedCrossRef
69.
Hirata T, Osuga Y, Hamasaki K, et al. Interleukin (IL)-17A stimulates IL-8 secretion, cyclooxygensase-2 expression, and cell proliferation of endometriotic stromal cells. Endocrinology. 2008;149:1260–7.PubMedCrossRef
70.
Zhang L, Khayat A, Cheng H, Graves DT. The pattern of monocyte recruitment in tumors is modulated by MCP-1 expression and influences the rate of tumor growth. Lab Investig. 1997;76:579–90.PubMed
71.
Kelly RW, Carr GG, Riley SC. The inhibition of synthesis of a beta-chemokine, monocyte chemotactic protein-1 (MCP-1) by progesterone. Biochem Biophys Res Commun. 1997;239:557–61.PubMedCrossRef
72.
73.
74.
Mancias JD, Wang X, Gygi SP, Harper JW, Kimmelman AC. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature. 2014;509:105–9.PubMedPubMedCentralCrossRef
75.
76.
Defrère S, Van Langendonckt A, Vaesen S, et al. Iron overload enhances epithelial cell proliferation in endometriotic lesions induced in a murine model. Hum Reprod. 2006;21:2810–6.PubMedCrossRef
77.
Van Langendonckt A, Casanas-Roux F, Donnez J. Iron overload in the peritoneal cavity of women with pelvic endometriosis. Fertil Steril. 2002;78:712–8.PubMedCrossRef
78.
Yamaguchi K, Mandai M, Toyokuni S, et al. Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the iron-induced persistent oxidative stress. Clin Cancer Res. 2008;14:32–40.PubMedCrossRef
79.
Seidman JD. The presence of mucosal iron in the fallopian tube supports the “incessant menstruation hypothesis” for ovarian carcinoma. Int J Gynecol Pathol. 2013;32:454–8.PubMedCrossRef
80.
Emori MM, Drapkin R. The hormonal composition of follicular fluid and its implications for ovarian cancer pathogenesis. Reprod Biol Endocrinol. 2014;12:60.PubMedPubMedCentralCrossRef
81.
Shigeta S, Toyoshima M, Kitatani K, Ishibashi M, Usui T, Yaegashi N. Transferrin facilitates the formation of DNA double-strand breaks via transferrin receptor 1: the possible involvement of transferrin in carcinogenesis of high-grade serous ovarian cancer. Oncogene. 2016;35:3577–86.PubMedCrossRef
82.
Singh AK, Chattopadhyay R, Chakravarty B, Chaudhury K. Markers of oxidative stress in follicular fluid of women with endometriosis and tubal infertility undergoing IVF. Reprod Toxicol. 2013;42:116–24.PubMedCrossRef
83.
Da Broi MG, de Albuquerque FO, de Andrade AZ, Cardoso RL, Jordão Junior AA, Navarro PA. Increased concentration of 8-hydroxy-2’-deoxyguanosine in follicular fluid of infertile women with endometriosis. Cell Tissue Res. 2016;366:231–42.PubMedCrossRef
84.
Sanchez AM, Papaleo E, Corti L, et al. Iron availability is increased in individual human ovarian follicles in close proximity to an endometrioma compared with distal ones. Hum Reprod. 2014;29:577–83.PubMedCrossRef
85.
Benaglia L, Paffoni A, Mangiarini A, et al. Intrafollicular iron and ferritin in women with ovarian endometriomas. Acta Obstet Gynecol Scand. 2015;94:646–53.PubMedCrossRef
86.
Bahar-Shany K, Brand H, Sapoznik S, et al. Exposure of fallopian tube epithelium to follicular fluid mimics carcinogenic changes in precursor lesions of serous papillary carcinoma. Gynecol Oncol. 2014;132:322–7.PubMedCrossRef
87.
Huang H-S, Chu S-C, Hsu C-F, et al. Mutagenic, surviving and tumorigenic effects of follicular fluid in the context of p53 loss: initiation of fimbria carcinogenesis. Carcinogenesis. 2015;36:1419–28.PubMedCrossRef
88.
Lattuada D, Uberti F, Colciaghi B, et al. Fimbrial cells exposure to catalytic iron mimics carcinogenic changes. Int J Gynecol Cancer. 2015;25:389–98.PubMedCrossRef
89.
Uberti F, Morsanuto V, Lattuada D, et al. Protective effects of vitamin D3 on fimbrial cells exposed to catalytic iron damage. J Ovarian Res. 2016;9:34.PubMedPubMedCentralCrossRef
90.
Yamaguchi K, Mandai M, Oura T, et al. Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene. 2010;29:1741–52.PubMedCrossRef
91.
Joseph S, Mahale SD. Endometriosis Knowledgebase: a gene-based resource on endometriosis. Database (Oxford). 2019;2019:baz062.CrossRef
92.
Ponomarenko I, Polonikov A, Verzilina I, Churnosov M. Molecular-genetic determinants of the development of endometriosis. Probl Gynecol Obstet Perinatol. 2019;18:82–6.
93.
94.
Vestergaard AL, Thorup K, Knudsen UB, et al. Oncogenic events associated with endometrial and ovarian cancers are rare in endometriosis. Mol Hum Reprod. 2011;17:758–61.PubMedCrossRef
95.
Bischoff FZ, Heard M, Simpson JL. Somatic DNA alterations in endometriosis: high frequency of chromosome 17 and p53 loss in late-stage endometriosis. J Reprod Immunol. 2002;55:49–644.PubMedCrossRef
96.
Sáinz de la Cuesta R, Izquierdo M, Cañamero M, Granizo JJ, Manzarbeitia F. Increased prevalence of p53 overexpression from typical endometriosis to atypical endometriosis and ovarian cancer associated with endometriosis. Eur J Obstet Gynecol Reprod Biol. 2004;113:87–93.PubMedCrossRef
97.
Laudanski P, Szamatowicz J, Kowalczuk O, Kuźmicki M, Grabowicz M, Chyczewski L. Expression of selected tumor suppressor and oncogenes in endometrium of women with endometriosis. Hum Reprod. 2009;24:1880–90.PubMedCrossRef
98.
Yamamoto S, Tsuda H, Takano M, Iwaya K, Tamai S, Matsubara O. PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma. J Pathol. 2011;225:189–94.PubMedCrossRef
99.
Sato N, Tsunoda H, Nishida M, et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res. 2000;60:7052–6.PubMed
100.
Anglesio MS, Bashashati A, Wang YK, et al. Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden. J Pathol. 2015;236:201–9.PubMedPubMedCentralCrossRef
101.
102.
Fuseya C, Horiuchi A, Hayashi A, et al. Involvement of pelvic inflammation-related mismatch repair abnormalities and microsatellite instability in the malignant transformation of ovarian endometriosis. Hum Pathol. 2012;43:1964–72.PubMedCrossRef
103.
Grassi T, Calcagno A, Marzinotto S, et al. Mismatch repair system in endometriotic tissue and eutopic endometrium of unaffected women. Int J Clin Exp Pathol. 2015;8:1867–77.PubMedPubMedCentral
104.
Yang W, Zhang Y, Fu F, Li R. High-resolution array-comparative genomic hybridization profiling reveals 20q13.33 alterations associated with ovarian endometriosis. Gynecol Endocrinol. 2013;29:603–7.PubMedCrossRef
105.
Mafra F, Mazzotti D, Pellegrino R, et al. Copy number variation analysis reveals additional variants contributing to endometriosis development. J Assist Reprod Genet. 2017;34:117–24.PubMedCrossRef
106.
107.
108.
Stamp JP, Gilks CB, Wesseling M, et al. BAF250a expression in atypical endometriosis and endometriosis-associated ovarian cancer. Int J Gynecol Cancer. 2016;26:825–32.PubMedCrossRef
109.
Chene G, Ouellet V, Rahimi K, Barres V, Provencher D, Mes-Masson AM. The ARID1A pathway in ovarian clear cell and endometrioid carcinoma, contiguous endometriosis, and benign endometriosis. Int J Gynaecol Obstet. 2015;130:27–30.PubMedCrossRef
110.
Martínez-Salgado C, Rodríguez-Peña AB, López-Novoa JM. Involvement of small Ras GTPases and their effectors in chronic renal disease. Cell Mol Life Sci. 2008;65:477–92.PubMedCrossRef
111.
Rojas JM, Santos E. Ras genes and human cancer: different implications and different roles. Curr Genom. 2002;3:295–311.CrossRef
112.
113.
Baselga J. The EGFR as a target for anticancer therapy–focus on cetuximab. Eur J Cancer. 2001;37(Suppl 4):S16–22.PubMedCrossRef
114.
Stephen AG, Esposito D, Bagni RK, McCormick F. Dragging ras back in the ring. Cancer Cell. 2014;25:272–81.PubMedCrossRef
115.
116.
Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757–65.CrossRefPubMed
117.
Guo DF, Sun YL, Hamet P, Inagami T. The angiotensin II type 1 receptor and receptor-associated proteins. Cell Res. 2001;11:165–80.PubMedCrossRef
118.
Wang L, Proud CG. Regulation of the phosphorylation of elongation factor 2 by MEK-dependent signalling in adult rat cardiomyocytes. FEBS Lett. 2002;531:285–9.PubMedCrossRef
119.
Santibáñez JF, Guerrero J, Quintanilla M, Fabra A, Martínez J. Transforming growth factor-beta1 modulates matrix metalloproteinase-9 production through the Ras/MAPK signaling pathway in transformed keratinocytes. Biochem Biophys Res Commun. 2002;296:267–73.PubMedCrossRef
120.
Che W, Abe J, Yoshizumi M, et al. p160 Bcr mediates platelet-derived growth factor activation of extracellular signal-regulated kinase in vascular smooth muscle cells. Circulation. 2001;104:1399–406.PubMedCrossRef
121.
Robin P, Boulven I, Bôle-Feysot C, Tanfin Z, Leiber D. Contribution of PKC-dependent and -independent processes in temporal ERK regulation by ET-1, PDGF, and EGF in rat myometrial cells. Am J Physiol Cell Physiol. 2004;286:C798–806.PubMedCrossRef
122.
Lin C-C, Shyr M-H, Chien C-S, et al. Thrombin-stimulated cell proliferation mediated through activation of Ras/Raf/MEK/MAPK pathway in canine cultured tracheal smooth muscle cells. Cell Signal. 2002;14:265–75.PubMedCrossRef
123.
Rakhila H, Al-Akoum M, Bergeron M-E, et al. Promotion of angiogenesis and proliferation cytokines patterns in peritoneal fluid from women with endometriosis. J Reprod Immunol. 2016;116:1–6.PubMedCrossRef
124.
Zhang Q, Duan J, Liu X, Guo S-W. Platelets drive smooth muscle metaplasia and fibrogenesis in endometriosis through epithelial-mesenchymal transition and fibroblast-to-myofibroblast transdifferentiation. Mol Cell Endocrinol. 2016;428:1–16.PubMedCrossRef
125.
Loverro G, Maiorano E, Napoli A, Selvaggi L, Marra E, Perlino E. Transforming growth factor-beta 1 and insulin-like growth factor-1 expression in ovarian endometriotic cysts: a preliminary study. Int J Mol Med. 2001;7:423–9.PubMed
126.
Guo S-W, Du Y, Liu X. Endometriosis-derived stromal cells secrete thrombin and thromboxane A2, inducing platelet activation. Reprod Sci. 2016;23:1044–52.PubMedCrossRef
127.
Nakao T, Chishima F, Sugitani M, Tsujimura R, Hayashi C, Yamamoto T. Expression of angiotensin II types 1 and 2 receptors in endometriotic lesions. Gynecol Obstet Invest. 2017;82:294–302.PubMedCrossRef
128.
Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med. 2005;11:63–70.PubMedCrossRef
129.
Shahrabi-Farahani M, Shahbazi S, Mahdian R, Amini-Moghaddam S. K-Ras 4A transcript variant is up-regulated in eutopic endometrium of endometriosis patients during proliferative phase of menstrual cycle. Arch Gynecol Obstet. 2015;292:225–9.PubMedCrossRef
130.
Farahani MS, Shahbazi S, Moghaddam SA, Mahdian R. Evaluation of KRAS gene expression and LCS6 variant in genomic and cell-free DNA of Iranian women with endometriosis. Reprod Sci. 2015;22:679–84.PubMedPubMedCentralCrossRef
131.
Yotova IY, Quan P, Leditznig N, Beer U, Wenzl R, Tschugguel W. Abnormal activation of Ras/Raf/MAPK and RhoA/ROCKII signalling pathways in eutopic endometrial stromal cells of patients with endometriosis. Hum Reprod. 2011;26:885–97.PubMedCrossRef
132.
Cheng C, Licence D, Cook E, et al. Activation of mutated K-ras in donor endometrial epithelium and stroma promotes lesion growth in an intact immunocompetent murine model of endometriosis. J Pathol. 2011;224:261–9.PubMedCrossRef
133.
Stewart CJR, Leung Y, Walsh MD, Walters RJ, Young JP, Buchanan DD. KRAS mutations in ovarian low-grade endometrioid adenocarcinoma: association with concurrent endometriosis. Hum Pathol. 2012;43:1177–83.PubMedCrossRef
134.
Ueda M, Yamashita Y, Takehara M, et al. Survivin gene expression in endometriosis. J Clin Endocrinol Metab. 2002;87:3452–9.PubMedCrossRef
135.
Laudanski P, Szamatowicz J, Ramel P. Matrix metalloproteinase-13 and membrane type-1 matrix metalloproteinase in peritoneal fluid of women with endometriosis. Gynecol Endocrinol. 2005;21:106–10.PubMedCrossRef
136.
Chung HW, Lee JY, Moon H-S, et al. Matrix metalloproteinase-2, membranous type 1 matrix metalloproteinase, and tissue inhibitor of metalloproteinase-2 expression in ectopic and eutopic endometrium. Fertil Steril. 2002;78:787–95.PubMedCrossRef
137.
Levakov S, Gromova T, Kedrova A, Sheshukova N. Endometriosis-associated ovarian cancer. Women Reprod Syst Tumors. 2016;12:47–51.CrossRef
138.
Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Mod Pathol. 2012;25:615–24.PubMedCrossRef
139.
140.
Nishikimi K, Kiyokawa T, Tate S, Iwamoto M, Shozu M. ARID1A expression in ovarian clear cell carcinoma with an adenofibromatous component. Histopathology. 2015;67:866–71.PubMedCrossRef
141.
Guan B, Rahmanto YS, Wu R-C, et al. Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis. J Natl Cancer Inst. 2014;106:dju146.PubMedPubMedCentralCrossRef
142.
Tomasetti C, Vogelstein B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science. 2015;347:78–81.PubMedPubMedCentralCrossRef
143.
Minlikeeva AN, Freudenheim JL, Eng KH, et al. History of comorbidities and survival of ovarian cancer patients, results from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomark Prev. 2017;26:1470–3.CrossRef
144.
Zou Y, Zhou J-Y, Guo J-B, et al. The presence of KRAS, PPP2R1A and ARID1A mutations in 101 Chinese samples with ovarian endometriosis. Mutat Res. 2018;809:1–5.PubMedCrossRef
145.
Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma. Virchows Arch Int J Pathol. 2012;460:77–87.CrossRef
146.
147.
Puc J, Keniry M, Li HS, et al. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell. 2005;7:193–204.PubMedCrossRef
148.
de Abreu JP, Rebelatto CLK, Savari CA, et al. The effect of mesenchymal stem cells on fertility in experimental retrocervical endometriosis. Rev Bras Ginecol Obstet. 2017;39:217–23.PubMedCrossRef
149.
Puc J, Parsons R. PTEN loss inhibits CHK1 to cause double stranded-DNA breaks in cells. Cell Cycle Georget Tex. 2005;4:927–9.CrossRef
150.
Obata K, Hoshiai H. Common genetic changes between endometriosis and ovarian cancer. Gynecol Obstet Invest. 2000;50(Suppl 1):39–433.PubMedCrossRef
151.
Obata K, Morland SJ, Watson RH, et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res. 1998;58:2095–7.PubMed
152.
Xu B, Hamada S, Kusuki I, Itoh R, Kitawaki J. Possible involvement of loss of heterozygosity in malignant transformation of ovarian endometriosis. Gynecol Oncol. 2011;120:239–46.PubMedCrossRef
153.
Zhang H, Zhao X, Liu S, Li J, Wen Z, Li M. 17betaE2 promotes cell proliferation in endometriosis by decreasing PTEN via NFkappaB-dependent pathway. Mol Cell Endocrinol. 2010;317:31–433.PubMedCrossRef
154.
Martini M, Ciccarone M, Garganese G, et al. Possible involvement of hMLH1, p16(INK4a) and PTEN in the malignant transformation of endometriosis. Int J Cancer. 2002;102:398–406.PubMedCrossRef
155.
156.
Li M-Q, Luo X-Z, Meng Y-H, et al. CXCL8 enhances proliferation and growth and reduces apoptosis in endometrial stromal cells in an autocrine manner via a CXCR1-triggered PTEN/AKT signal pathway. Hum Reprod. 2012;27:2107–16.PubMedCrossRef
157.
158.
Lv J, Zhu Q, Jia X, Yu N, Li Q. In vitro and in vivo effects of tumor suppressor gene PTEN on endometriosis: an experimental study. Med Sci Monit. 2016;22:3727–36.PubMedPubMedCentralCrossRef
159.
Ferretti E, Schulz H, Talarico D, Blasi F, Berthelsen J. The PBX-regulating protein PREP1 is present in different PBX-complexed forms in mouse. Mech Dev. 1999;83:53–64.PubMedCrossRef
160.
Selleri L, Depew MJ, Jacobs Y, et al. Requirement for Pbx1 in skeletal patterning and programming chondrocyte proliferation and differentiation. Development. 2001;128:3543–57.PubMed
161.
Marshall H, Nonchev S, Sham MH, Muchamore I, Lumsden A, Krumlauf R. Retinoic acid alters hindbrain Hox code and induces transformation of rhombomeres 2/3 into a 4/5 identity. Nature. 1992;360:737–41.PubMedCrossRef
162.
Dubrulle J, McGrew MJ, Pourquié O. FGF signaling controls somite boundary position and regulates segmentation clock control of spatiotemporal Hox gene activation. Cell. 2001;106:219–32.PubMedCrossRef
163.
Miller C, Pavlova A, Sassoon DA. Differential expression patterns of Wnt genes in the murine female reproductive tract during development and the estrous cycle. Mech Dev. 1998;76:91–9.PubMedCrossRef
164.
Cunha GR. Stromal induction and specification of morphogenesis and cytodifferentiation of the epithelia of the Mullerian ducts and urogenital sinus during development of the uterus and vagina in mice. J Exp Zool. 1976;196:361–70.PubMedCrossRef
165.
Branford WW, Benson GV, Ma L, Maas RL, Potter SS. Characterization of Hoxa-10/Hoxa-11 transheterozygotes reveals functional redundancy and regulatory interactions. Dev Biol. 2000;224:373–87.PubMedCrossRef
166.
Vainio S, Heikkilä M, Kispert A, Chin N, McMahon AP. Female development in mammals is regulated by Wnt-4 signalling. Nature. 1999;397:405–9.PubMedCrossRef
167.
Mericskay M, Kitajewski J, Sassoon D. Wnt5a is required for proper epithelial-mesenchymal interactions in the uterus. Development. 2004;131:2061–72.PubMedCrossRef
168.
Hayashi K, Yoshioka S, Reardon SN, et al. WNTs in the neonatal mouse uterus: potential regulation of endometrial gland development. Biol Reprod. 2011;84:308–19.PubMedCrossRef
169.
Kühl M, Sheldahl LC, Park M, Miller JR, Moon RT. The Wnt/Ca2+ pathway: a new vertebrate Wnt signaling pathway takes shape. Trends Genet TIG. 2000;16:279–83.PubMedCrossRef
170.
171.
Valkenburg KC, Graveel CR, Zylstra-Diegel CR, Zhong Z, Williams BO. Wnt/β-catenin signaling in normal and cancer stem cells. Cancers. 2011;3:2050–79.PubMedPubMedCentralCrossRef
172.
Kuo H-H, Huang C-Y, Ueng S-H, Huang K-G, Lee C-L, Yen C-F. Unexpected epithelial ovarian cancers arising from presumed endometrioma: a 10-year retrospective analysis. Taiwan J Obstet Gynecol. 2017;56:55–61.PubMedCrossRef
173.
Gadducci A, Lanfredini N, Tana R. Novel insights on the malignant transformation of endometriosis into ovarian carcinoma. Gynecol Endocrinol. 2014;30:612–7.PubMedCrossRef
174.
Kurman RJ, International Agency for Research on Cancer, World Health Organization. WHO classification of tumours of female reproductive organs, vol. 4. Lyon: International Agency for Research on Cancer; 2014.
175.
Kaku T, Ogawa S, Kawano Y, et al. Histological classification of ovarian cancer. Med Electron Microsc. 2003;36:9–17.PubMedCrossRef
176.
Anglesio MS, Yong PJ. Endometriosis-associated ovarian cancers. Clin Obstet Gynecol. 2017;60:711–27.PubMedCrossRef
177.
Xiao W, Awadallah A, Xin W. Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma. Int J Clin Exp Pathol. 2012;5:642–50.PubMedPubMedCentral
178.
Coatham M, Li X, Karnezis AN, et al. Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas. Mod Pathol. 2016;29:1586–93.PubMedCrossRef
179.
180.
Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013;45:1127–33.PubMedPubMedCentralCrossRef
181.
Sapalidis K, Machairiotis N, Zarogoulidis P, et al. Genes’ interactions: a major contributor to the malignant transformation of endometriosis. Int J Mol Sci. 2019;20:1842.PubMedCentralCrossRef
182.
Berker B, Seval M. Problems with the diagnosis of endometriosis. Womens Health. 2015;11:597–601.
183.
184.
Huhtinen K, Suvitie P, Hiissa J, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. 2009;100:1315–9.PubMedPubMedCentralCrossRef
185.
Leyland N, Casper R, Laberge P, Singh SS, SOGC. Endometriosis: diagnosis and management. J Obstet Gynaecol Can. 2010;32:S1–32.PubMedCrossRef
186.
Wykes CB, Clark TJ, Khan KS. Accuracy of laparoscopy in the diagnosis of endometriosis: a systematic quantitative review. BJOG. 2004;111:1204–12.PubMedCrossRef
187.
Hori Y, SAGES Guidelines Committee. Diagnostic laparoscopy guidelines: This guideline was prepared by the SAGES Guidelines Committee and reviewed and approved by the Board of Governors of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), November 2007. Surg Endosc. 2008;22:1353–83.PubMedCrossRef
188.
Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril. 2012;98:511–9.PubMedCrossRef
189.
Eskenazi B, Warner ML. Epidemiology of endometriosis. Obstet Gynecol Clin North Am. 1997;24:235–58.PubMedCrossRef
190.
Burghaus S, Häberle L, Schrauder MG, et al. Endometriosis as a risk factor for ovarian or endometrial cancer—results of a hospital-based case–control study. BMC Cancer. 2015;15:751.PubMedPubMedCentralCrossRef
191.
Wykes CB, Clark TJ, Chakravati S, Mann CH, Gupta JK. Efficacy of laparoscopic excision of visually diagnosed peritoneal endometriosis in the treatment of chronic pelvic pain. Eur J Obstet Gynecol Reprod Biol. 2006;125:129–33.PubMedCrossRef
192.
Moon H-S, Shim JE, Lee SR, Jeong K. The comparison of robotic single-site surgery to single-port laparoendoscopic surgery for the treatment of advanced-stage endometriosis. J Laparoendosc Adv Surg Tech A. 2018;28:1483–8.PubMedCrossRef
193.
Practice Committee of the American Society for Reproductive Medicine. Endometriosis and infertility. Fertil Steril. 2006;86:S156–160.
194.
Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil Steril. 2014;101:927–35.CrossRef
195.
Karaman Y, Uslu H. Complications and their management in endometriosis surgery. Womens Health. 2015;11:685–92.
196.
Chan LY, So WW, Lao TT. Rapid recurrence of endometrioma after transvaginal ultrasound-guided aspiration. Eur J Obstet Gynecol Reprod Biol. 2003;109:196–8.PubMedCrossRef
197.
Okagaki R, Osuga Y, Momoeda M, Tsutsumi O, Taketani Y. Laparoscopic findings after ultrasound-guided transvaginal ethanol sclerotherapy for ovarian endometrial cyst. Hum Reprod. 1999;14:270.PubMedCrossRef
198.
Vercellini P, Somigliana E, Viganò P, Abbiati A, Barbara G, Crosignani PG. Surgery for endometriosis-associated infertility: a pragmatic approach. Hum Reprod. 2009;24:254–69.PubMedCrossRef
199.
Bedaiwy MA, Alfaraj S, Yong P, Casper R. New developments in the medical treatment of endometriosis. Fertil Steril. 2017;107:555–65.PubMedCrossRef
200.
Streuli I, de Ziegler D, Borghese B, Santulli P, Batteux F, Chapron C. New treatment strategies and emerging drugs in endometriosis. Expert Opin Emerg Drugs. 2012;17:83–104.CrossRef
201.
Streuli I, de Ziegler D, Santulli P, et al. An update on the pharmacological management of endometriosis. Expert Opin Pharmacother. 2013;14:291–305.PubMedCrossRef
202.
Taylor HS, Giudice LC, Lessey BA, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med. 2017;377:28–40.PubMedCrossRef
203.
Dawson A, Fernandez ML, Anglesio M, Yong PJ, Carey MS. Endometriosis and endometriosis-associated cancers: new insights into the molecular mechanisms of ovarian cancer development. Ecancermedicalscience. 2018;12:803.PubMedPubMedCentralCrossRef
Metadata
Title
Malignant Transformation and Associated Biomarkers of Ovarian Endometriosis: A Narrative Review
Authors
Liudmila M. Mikhaleva
Aleksandr I. Davydov
Olga I. Patsap
Elizaveta V. Mikhaylenko
Vladimir N. Nikolenko
Margarita E. Neganova
Sergey G. Klochkov
Siva G. Somasundaram
Cecil E. Kirkland
Gjumrakch Aliev
Publication date
01-06-2020
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 6/2020
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-020-01363-5

Other articles of this Issue 6/2020

Advances in Therapy 6/2020 Go to the issue

Original Research

Micronized Purified Flavonoid Fraction in Hemorrhoid Disease: A Systematic Review and Meta-Analysis

Original Research

The Relationship Between White Adipose Tissue Inflammation and Overweight/Obesity in Chinese Female Breast Cancer: A Retrospective Study

Original Research

The Impact of Baseline Pain Intensity on the Analgesic Efficacy of Ibuprofen/Caffeine in Patients with Acute Postoperative Dental Pain: Post Hoc Subgroup Analysis of a Randomised Controlled Trial

Original Research

Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis

Original Research

Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Acetylsalicylic Acid in Fixed-Dose Combination with Clopidogrel Versus Enteric Aspirin in Chinese Subjects Under Fasting Conditions: A Phase 1, Open-Label, Randomized, Crossover Study

Original Research

Persistence and Adherence to ICS/LABA Drugs in UK Patients with Asthma: A Retrospective New-User Cohort Study

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits